DAVID GRANOVSKY

Posts Tagged ‘Centers for Disease Control and Prevention’

PRP TREATMENTS SHOW GREAT POTENTIAL

In ALL ARTICLES, SCIENCE & STEM CELLS, STEM CELLS IN THE NEWS on February 14, 2013 at 9:00 am

Extremity-joint-knee

Platelet-Rich Plasma (Prp) Treatment Shows Potential for Knee Osteoarthritis

A study by researchers from Hospital for Special Surgery has shown that platelet-rich plasma (PRP) holds great promise for treating patients with knee osteoarthritis. The treatment improved pain and function, and in up to 73% of patients, appeared to delay the progression of osteoarthritis, which is a progressive disease. The study appears online, ahead of print, in the Clinical Journal of Sports Medicine.

“This is a very positive study,” said Brian Halpern, M.D., chief of the Primary Care Sports Medicine Service at Hospital for Special Surgery, New York City, and lead author of the study.

Several treatments for osteoarthritis exist, including exercise, weight control, bracing, nonsteroidal anti-inflammatories, Tylenol, cortisone shots and viscosupplementation, a procedure that involves injecting a gel-like substance into the knee to supplement the natural lubricant in the joint. A new treatment that is being studied by a small number of doctors is PRP injections. PRP, which is produced from a patient’s own blood, delivers a high concentration of growth factors to arthritic cartilage that can potentially enhance healing.

“You take a person’s blood, you spin it down, you concentrate the platelets, and you inject a person’s knee with their own platelets in a concentrated form,” said Dr. Halpern. “This then activates growth factors and stem cells to help repair the tissue, if possible, calm osteoarthritic symptoms and decrease inflammation.”

In the new study, researchers at Hospital for Special Surgery enrolled patients with early osteoarthritis, gave them each an injection of PRP (6-mL), and then monitored them for one year. Fifteen patients underwent clinical assessments at baseline, one week, and one, three, six, and 12 months. At these time points, clinicians used validated tools to assess overall knee pain, stiffness and function, as well as a patient’s ability to perform various activities of daily living. At baseline and then one year after the PRP injection, physicians also evaluated the knee cartilage with magnetic resonance imaging (MRI), something that has not previously been done by researchers in other PRP studies. The radiologists reading the MRIs did not know whether the examination was performed before or after the PRP treatment.

“The problem with a lot of the PRP studies is that most people have just used subjective outcome instruments, such as pain and function scores,” said Hollis Potter, M.D., chief of the Division of Magnetic Resonance Imaging at Hospital for Special Surgery, another author of the study. “But even when patients are blinded, they know there has been some treatment, so there is often some bias interjected into those types of studies. When you add MRI assessment, it shows you the status of the disease at that time, regardless of whether the patient is symptomatic or asymptomatic or they have good or poor function in the knee. You find out what the cartilage actually looks like. We can noninvasively assess the matrix or the building blocks of cartilage.”

While previous studies have shown that patients with osteoarthritis can lose roughly five percent of knee cartilage per year, the HSS investigators found that a large majority of patients in their study had no further cartilage loss. “The knee can be divided into three compartments, the medial compartment, the lateral compartment and the patellofemoral compartment,” said Dr. Halpern. “If we look at these compartments individually, which we did, in at least 73% of these cases, there was no progression of arthritis per compartment at one year. That is very significant, because longitudinal studies suggest a four to six percent progression of arthritis at one year.”

Treatment with PRP was also useful in improving pain, stiffness and function. The investigators found that pain, measured by a standard test called the Western Ontario and McMaster Universities Arthritis Index, significantly improved with a reduction of 41.7% at six months and 55.9% at one year. On a pain scale commonly used by clinicians called the Visual Analog Scale, pain was reduced by 56.2% at six months and 58.9% at one year. Functional scores improved by 24.3% at one year. Activity of Daily Living Scores also showed a significant increase at both six months (46.8%) and one year (55.7%).

“We are entering into an era of biologic treatment, which is incredibly ideal, where you can use your own cells to try to help repair your other cells, rather than using a substance that is artificial,” Dr. Halpern said. “The downside is next to zero and the upside is huge.” Dr. Halpern pointed out, however, that the study is a small case series and PRP needs to be pitted against a traditionally treated group in a randomized, controlled trial.

Osteoarthritis, which causes pain and joint stiffness, impacts over 27 million Americans and is a leading cause of disability. According to statistics from the Centers for Disease Control and Prevention, overall osteoarthritis affects 13.9% of adults aged 25 and older and 33.6% of those older than 65. The disease is characterized by degeneration of cartilage and its underlying bone within a joint as well as bony overgrowth. Disease onset is gradual and usually begins after the age of 40.

sciencedaily.com

RELATED ARTICLES

Advertisements

Baby monkeys given standard doses of popular vaccines develop autism symptoms

In ALL ARTICLES, OFF THE BEATEN PATH on January 17, 2013 at 10:23 pm

monkey-vaccines-autismautistic child
Vaccines In University of Pittsburgh Vaccine Study

Apr 29th, 2012 | By | Category: Catherine Frompovich, Recent Articles, Recent Articles, Top Stories

A University of Pittsburgh study showed vaccines altered the behavior in monkeys.

Someone did perform safety studies the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) should have mandated be performed and vetted BEFORE numerous vaccines were released into the public sector for mass vaccinations.

Lead investigator Laura Hewitson, PhD, probably dropped a bombshell when she and her colleagues completed a macaque monkey (primates) study of the very same vaccines given to children during 1994-1999, i.e., the Measles-Mumps-Rubella (MMR) vaccine and several Thimerosal mercury-containing vaccines injected into children during that time frame when the autism spectrum disorder skyrocketed.

The results of that pilot study were published as a Research Paper in Acta Neurobiological Experimentals in 2010 and titled “Influence of pediatric vaccines on amydgala growth and opioid ligand binding in rhesus macaque infants: A pilot study.”

TO SEE THE ORIGINAL STUDY:  Influence of pediatric vaccines on amygdala growth and opioid ligand binding in rhesus macaque infants: A pilot study   http://www.ane.pl/pdf/7020.pdf

[1] Even though there was alleged controversy revolving around Hewitson’s monkey studies, e.g., charges of conflicts of interest since she filed a claim with the vaccine court on behalf of her child, [2] the information generated needs to be revisited and duplicate studies need to be undertaken. Why haven’t they?  Is there too much influence from vaccine makers not to do them? Parents need to make demands on the U.S. Congress to require such safety studies on monkeys be duplicated immediately, plus suspend all mandates on vaccinations until the study results are in.  Did Dr Hewitson become another professional persona non-grata because she may have been on the right track?

Congress needs to consider seriously the Hewitson, et al. report that stated:

“Vaccine-exposed and saline-injected control infants [monkeys] underwent MRI and PET imaging at approximately 4 and 6 months of age, representing two specific timeframes within the vaccination schedule. …

“These results suggest that maturational changes in amygdala volume and the binding capacity of [11C]DPN in the amygdala was significantly altered in infant macaques receiving the vaccine schedule.” [1]

That alone should be the explicit reason for duplicating the monkey study with independent non-pharmaceutical industry conflict of interest scientists.

In this author’s opinion, no one has bigger conflicts of interest in study outcomes than the pharmaceutical makers who routinely perform them.  Those are the very studies that should be subject to the same criticism as Dr Hewitson’s.  Why aren’t they?  Good question?

For those keeping track data, ASD went from 1 in 5,000 in the 1990s to the recently acknowledged [March 2012] figures of 1 in 88 along with 1 in 6 children in the USA having developmental disabilities.  These stats were generated for data in the years 2006 to 2008. [3] There’s a 4 to 6 year lag time.  Could ASD be 1 in 50 by now at the rate it is escalating?, especially since there’s a heavier push on mandates for vaccinations.

According to the Hewitson, et al. research study, biological changes and altered behaviors did occur in vaccinated monkeys, which resembled and were similar to those observed in ASD diagnosed children.  However, there were no such symptoms showing or present in unvaccinated monkeys.  Don’t you just gotta love those little monkeys!  Guess what else the ASD monkeys came up with, and Dr Wakefield is gonna like this one: Gastrointestinal problems manifested in vaccinated macaques such as “many significant differences in the GI tissue gene expression profiles between vaccinated and unvaccinated animals.” [3] It’s been a deeply debated topic within medicine that vaccinated children who contract ASD also have GI tract issues.  Personally, I gotta wonder how the British Medical Journal is going to deal with encrusted dried egg on its face when duplicate studies confirm the Hewitson monkey results.  Perhaps the infamous BMJ retraction of the Wakefield article and Doctor’s professional evisceration, commonly referred to as the “Wakefield Syndrome,” euphemistically speaking is medicine protecting its vested interests.

Those little monkeys, however, came up with some other significant information that led former National Institutes of Health director Dr Bernadine Healy to voice some bon mots like:

“I think public health officials have been too quick to dismiss the hypothesis as ‘irrational,’ without sufficient studies of causation…without studying the population that got sick.”

“I have not seen major studies that focus on 300 kids who got autistic symptoms within a period of a few weeks of the vaccines.” [4]

Perhaps the most on-point quote regarding the monkey study came from Scott Bono, the National Autism Association chairman, i.e., something those who are accused of being against vaccinations have been questioning and demanding:

“To date, the CDC has conducted no safety testing on the possible harmful effects of simultaneously administering multiple vaccines to infants, and has steadfastly refused to state a preference for mercury-free vaccines to be given to children and pregnant women.  It’s time for HHS and Congress to step in and take vaccine safety away from the CDC.”  [4]

This author’s retort to Mr. Bono’s remark is that vaccine safety should be taken away from the Food and Drug Administration too!  I’d like to remind readers that Congress is more at fault than anyone in this vaccine debacle.  Congress has oversight and it has dropped the ball big time, probably due to all the lobbyists from Big Pharma who prowl the halls of Congress with deep pockets and nice expensive luncheon dates.

One of the issues I feel Congress has been remiss about is that it has not demanded safety studies and interaction of multiple vaccines studies BEFORE being placed into the marketplace.  According to common and accepted knowledge, no such safety research or studies have been done on the current childhood vaccination regimen, except until the Hewitson ‘monkey business’ that was funded by independent, private money, for which everyone, I think, should be eternally grateful. However, the study had to be shot down since it was not favorable to vaccine makers.  Why isn’t someone else duplicating the monkey studies?  Are they afraid of becoming another victim of science?  Why, when isn’t that what medical science should be all about: investigating problems and theories, publishing results, and interacting with other sciences, NOT excommunication as if they were breaking some religious dogma.  Or, do they, in some vested interests minds?

Current Vaccine Safety Activism in Congress

Now here is something every VacTruth reader should consider seriously: Supporting Congressman Dan Burton’s (R-5-IN) request to the House Committee on Oversight and Government Reform Chairman Darrell Issa to hold hearings on the Vaccination Injury Compensation Program. Back on January 12, 2011, this writer filed a Whistleblower’s Complaint on Vaccines with Chairman Issa and has yet to receive an acknowledgement of that filing.

Isn’t about time to revisit, update, and do more extensive research into the Autism Spectrum Disorder pandemic that is spreading globally?

April 24, 2012 Congressman Burton posted a letter to The Hill’s Congress Blog titled, “It is time to re-engage on the autism epidemic.”  He also wants to pass legislation to force the President to address the ASD epidemic and its impact on Americans.  Burton is committed to helping millions of children, adults, and families afflicted with ASD.  We need to support Congressman Burton ASAP and here’s how:

  1. Contact the Canary Party to support their Facebook pages to hold Congressional hearings and a White House Conference on Autism.  Contact News@CanaryParty.org.
  2. Contact Congressman Darrell Issa at the Oversight and Government Reform Committee at 2157 Rayburn House Office Bldg., Washington, DC 20515 or preferably telephone your request for Autism Investigation Hearings to 202-225-5074.

For those who want to know about this information, the National Autism Association (www.nationalautism.org) will be holding a rally for toxin-free immunizations in Washington, DC on June 4, 2012, titled “Green Our Vaccines,” which this author thinks is an oxymoron.  How can you green vaccines when every ingredient is toxic?  Just check out the CDC’s PinkBook Vaccine Excipient & Media Summary at http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf.

Before I leave this article, I would like VacTruth readers to know that my colleague who also writes for VacTruth, Laraine C Abbey, RN (retired) and I co-edited a 150 page monograph in January 2011 titled Vaccines & Vaccinations: The Need for Congressional Investigation, which you can read in full on VacTruth at http://vactruth.com/vaccines-vaccinations-the-need-for-congressional-investigation/.

Apparently others have read it and agree.

Congressman Burton, Nurse Abbey and I congratulate you on taking the stand you have, and we offer you our resources in obtaining a Congressional investigation.

President Obama, Nurse Abbey and I respectfully request a White House conference on Autism, and we offer you our resources to effectuate a non-biased conference.

VacTruth readers, I charge you with spreading this information and article as far and wide as you possibly can so that we can get an investigation that ought to be open, not biased, and the scientific facts—nothing but the facts, like those the monkeys finally had to prove.  It was not monkey business; it’s the real deal.

via http://vactruth.com/2012/04/29/monkeys-get-autism/

References:

[1] http://www.ane.pl/pdf/7020.pdf

[2] http://leftbrainrightbrain.co.uk/2010/07/laura-hewitson-has-left-the-university-of-pittsburgh/

[3] http://www.cdc.gov/ncbddd/autism/data.html

[4] http://www.vaccineriskawareness.com/Infant-Vaccines-Produce-Autism-Symptoms-In-Primates

AND BY THE WAY…

Court Awards $969,474.91 for MMR Vaccine Causing Boy’s Autism

http://vactruth.com/2013/01/18/mmr-vaccine-causing-autism/

STEM CELL TREATMENTS TO BATTLE DMD (DUCHENNE MUSCULAR DYSTROPHY)

In ALL ARTICLES, SCIENCE & STEM CELLS, STEM CELLS IN THE NEWS on January 15, 2013 at 9:00 am

herzmuskelzellen-gesund,property=bild,bereich=bio,sprache=en

Stem-Cell Approach Shows Promise for Duchenne Muscular Dystrophy

“Researchers have shown that transplanting stem cells derived from normal mouse blood vessels into the hearts of mice that model the pathology associated with Duchenne muscular dystrophy (DMD) prevents the decrease in heart function associated with DMD.”

Their findings appear in the journal Stem Cells Translational Medicine.

Duchenne muscular dystrophy is a genetic disorder caused by a mutation in the gene for dystrophin, a protein that anchors muscle cells in place when they contract. Without dystrophin, muscle contractions tear cell membranes, leading to cell death. The lost muscle cells must be regenerated, but in time, scar tissue replaces the muscle cells, causing the muscle weakness and heart problems typical of DMD.

The U.S. Centers for Disease Control and Prevention estimates that DMD affects one in every 3,500 males. The disease is more prevalent in males because the dystrophin mutation occurs on the X chromosome; males have one X and one Y chromosome, so a male with this mutation will have DMD, while females have two X chromosomes and must have the mutation on both of them to have the disease. Females with the mutation in one X chromosome sometimes develop muscle weakness and heart problems as well, and may pass the mutation on to their children.  Although medical advances have extended the lifespans of DMD patients from their teens or 20s into their early 30s, disease-related damage to the heart and diaphragm still limits their lifespan.

“Almost 100 percent of patients develop dilated cardiomyopathy,” in which a weakened heart with enlarged chambers prevents blood from being properly pumped throughout the body, said University of Illinois comparative biosciences professor Suzanne Berry-Miller, who led the study. “Right now, doctors are treating the symptoms of this heart problem by giving patients drugs to try to prolong heart function, but that can’t replace the lost or damaged cells,” she said.

In the new study, the researchers injected stem cells known as aorta-derived mesoangioblasts (ADM) into the hearts of dystrophin-deficient mice that serve as a model for human DMD. The ADM stem cells have a working copy of the dystrophin gene.  This stem cell therapy prevented or delayed heart problems in mice that did not already show signs of the functional or structural defects typical of Duchenne muscular dystrophy, the researchers report.

Berry-Miller and her colleagues do not yet know why the functional benefits occur, but proposed three potential mechanisms. They observed that some of the injected stem cells became new heart muscle cells that expressed the lacking dystrophin protein. The treatment also caused existing stem cells in the heart to divide and become new heart muscle cells, and the stem cells stimulated new blood vessel formation in the heart. It is not yet clear which of these effects is responsible for delaying the onset of cardiomyopathy, Berry-Miller said.

“These vessel-derived cells might be good candidates for therapy, but the more important thing is the results give us new potential therapeutic targets to study.  Activating stem cells that are already present in the body to repair tissue would avoid the potential requirement to find a match between donors and recipients and potential rejection of the stem cells by the patients.”

Despite the encouraging results that show that stem cells yield a functional benefit when administered before pathology arises in DMD mouse hearts, a decline in function was seen in mice that already showed the characteristics of dilated cardiomyopathy. One of these characteristics is the replacement of muscle tissue with connective tissue, known as fibrosis.

This difference may occur, Berry-Miller said, as a result of stem cells landing in a pocket of fibrosis rather than in muscle tissue. The stem cells may then become fibroblasts that generate more connective tissue, increasing the amount of scarring and making heart function worse. This shows that the timing of stem cell insertion plays a crucial role in an increase in heart function in mice lacking the dystrophin protein.

She remains optimistic that these results provide a stepping-stone toward new clinical targets for human DMD patients.

“This is the only study so far where a functional benefit has been observed from stem cells in the dystrophin-deficient heart, or where endogenous stem cells in the heart have been observed to produce new muscle cells that replace those lost in DMD, so I think it opens up a new area to focus on in pre-clinical studies for DMD,” Berry-Miller said.

The Illinois Regenerative Medicine Institute supported this research.

http://www.sciencedaily.com/releases/2013/01/130114133350.htm

SNOWMEN RECEIVING STEM CELLS

STEM CELL THERAPIES TARGET OVARIAN CANCER

In STEM CELLS IN THE NEWS on January 9, 2013 at 10:46 pm

Picture-32

“Each year, about 20,000 women in the United States get ovarian cancer. Among women in the United States, ovarian cancer is the eighth most common cancer and the fifth leading cause of cancer death, after lung and bronchus, breast, colorectal, and pancreatic cancers. Ovarian cancer causes more deaths than any other cancer of the female reproductive system, but it accounts for only about 3% of all cancers in women. When ovarian cancer is found in its early stages, treatment is most effective.†”

Ovarian cancer stem cell study puts targeted therapies within reach

“Researchers at Yale School of Medicine have identified a key link between stem cell factors that fuel ovarian cancer’s growth and patient prognosis.  Yingqun Huang, M.D. and her colleagues have demonstrated a connection between two concepts that are revolutionizing the way cancer is treated.

First, the “cancer stem cell” idea suggests that at the heart of every tumor there is a small subset of difficult-to-identify tumor cells that fuel the growth of the bulk of the tumor. This concept predicts that ordinary therapies typically kill the bulk of tumor cells while leaving a rich environment for continued growth of the stem cell tumor population.  The second concept defines a critical role for the tumor cells’ “microenvironment,” which is the special environment required for cancer cell growth and spread.  “Both concepts have particular relevance for the treatment of adult solid tumors such as ovarian cancer, which has been notoriously difficult to diagnose and treat. Ovarian cancer patients are plagued by recurrences of tumor cells that are resistant to chemotherapy, ultimately leading to uncontrolled cancer growth and death.”

Cell Cycle Vol. 12, Issue 1

Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2009 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2013. Available at: http://www.cdc.gov/uscs.

Need information on a specific disease, click HERE for more information.

%d bloggers like this: